Chao Han, Ph.D.
Vice President of Early Development
Dr. Chao Han is the Vice President of Early Development and the Site Head of Tavotek Lab at Lower Gwynedd, Pennsylvania. He has more than 20 years of experience in preclinical discovery and clinical development of small molecule and biologic therapeutics. Prior to joining Tavotek, Dr. Han was the Scientific Director of Biologics Development Sciences at Janssen. He has worked at GSK as the DMPK Head and the Section Head of Pharmacokinetics and In Vivo Technology.
Dr. Han started his pharma industry career at GlaxoWellcome. He led the development of an automated animal PK system and was awarded GreatScience@R&D@GSK. Leading the DMPK activities, he contributed directly and through his leadership to the discovery of Tafinlar® and Mekinist®. He started his biologics journey by joining Centocor (later became Janssen) where he contributed to the development of Simponi®, Stelara®, and Darzalex®, as well as preclinical development of Talquetamab and Teclistamab. Contributing to the scientific community, he was a member of the IQ MABEL Working Group and a key author of a guidance white paper on selecting starting dose for the FIH trial. He also served Vice-Chair and Chair of the Early Development and Safety Steering Committee in ASCPT.
Dr. Han obtained his Ph.D. in Pharmacology and Therapeutics from the University of Manitoba, Faculty of Medicine, and MS and BS degrees in Chemistry from Nankai University. He received postgraduate training in the School of Pharmaceutical Sciences, University of California, San Francisco. He has published over 40 research papers and written six book chapters. He was the leading editor of a book titled Evaluation of Drug Candidates for Preclinical Development- Pharmacokinetics, Metabolism, Pharmaceutics, and Toxicology.